Cullin-RING Ligases as Promising Targets for Gastric Carcinoma Treatment

Pharmacol Res. 2021 Aug:170:105493. doi: 10.1016/j.phrs.2021.105493. Epub 2021 Feb 15.

Abstract

Gastric carcinoma has serious morbidity and mortality, which seriously threats human health. The studies on gastrointestinal cell biology have shown that the ubiquitination modification that occurs after protein translation plays an essential role in the pathogenesis of gastric carcinoma. Protein ubiquitination is catalyzed by E3 ubiquitin ligase and can regulate various substrate proteins in different cellular pathways. Cullin-RING E3 ligase (CRLs) is a representative of the E3 ubiquitin ligase family, which requires cullin (CUL) neddylation modification for activation to regulate homeostasis of ~20% of cellular proteins. The substrate molecules regulated by CRLs are often involved in many cell progressions such as cell cycle progression, cell apoptosis, DNA damage and repair. Given that CRLs play an important role in modulation of biological activities, so targeting a certain CULs member neddylation may be an attractive strategy for selectively controlling the cellular proteins levels to achieve the goal of cancer treatment. In this review, we will discuss the roles of CULs and Ring protein in gastric carcinoma and summarize the current neddylation modulators for gastric carcinoma treatment.

Keywords: Cullin-RING Ligases; Gastric carcinoma; Neddylation; Small-molecule modulators.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma / drug therapy*
  • Carcinoma / enzymology
  • Carcinoma / pathology
  • Cullin Proteins / metabolism*
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Molecular Targeted Therapy
  • Proteolysis
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / enzymology
  • Stomach Neoplasms / pathology
  • Ubiquitin-Protein Ligases / antagonists & inhibitors*
  • Ubiquitin-Protein Ligases / metabolism
  • Ubiquitination
  • Ubiquitins / metabolism*

Substances

  • Antineoplastic Agents
  • Cullin Proteins
  • Enzyme Inhibitors
  • Ubiquitins
  • CULL-RING ligase, human
  • Ubiquitin-Protein Ligases